ABT
Abbott Laboratories
Price performance
Sep 18, 2026About
Company activity
27 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/20 | ABT | 8-K | Abbott Laboratories Settles Portion of Preterm Infant Formula Litigation for $670 Million | — | — | — |
| 07/16 | ABT | 8-K | Abbott Laboratories Reports Strong Q2 2026 Results and Raises Full-Year EPS Guidance | — | — | — |
| 04/27 | ABT | 8-K | Abbott Laboratories Appoints New Board Member and Adopts New Incentive Stock Program | — | — | — |
| 04/17 | ABT | 8-K | Abbott Laboratories Announces Proposed Settlement in Shareholder Derivative Lawsuit | — | — | — |
| 04/16 | ABT | 8-K | Abbott Laboratories Announces First-Quarter 2026 Results and Acquisition of Exact Sciences | — | — | — |
| 03/23 | ABT | 8-K | Abbott Completes Acquisition of Exact Sciences, Strengthening Cancer Diagnostics Leadership | — | — | — |
| 03/09 | ABT | 8-K | Abbott Laboratories Completes $20 Billion Senior Notes Offering to Fund Exact Sciences Acquisition | — | — | — |
| 02/26 | ABT | 8-K | Abbott Laboratories Announces Issuance of Senior Notes to Fund Exact Sciences Acquisition | — | — | — |
| 02/20 | ABT | 8-K | Abbott Laboratories Amends Board Size in By-Laws | — | — | — |
| 01/22 | ABT | 8-K | Abbott Laboratories Announces 2025 Results and 2026 Outlook | — | — | — |
| 12/12/25 | ABT | 8-K | Abbott Laboratories Announces New Board Member and Bylaw Amendments | — | — | — |
| 11/21/25 | ABT | 8-K | Abbott Laboratories Announces Blackout Period for Employee Benefit Plans | — | — | — |
| 11/20/25 | ABT | 8-K | Abbott Laboratories Announces Agreement to Acquire Exact Sciences for $21 Billion | — | — | — |
| 10/15/25 | ABT | 8-K | Abbott Laboratories Announces Third-Quarter 2025 Results and Reaffirms Guidance | — | — | — |
| 07/17/25 | ABT | 8-K | Abbott Laboratories Announces Second-Quarter 2025 Results and Guidance | — | — | — |
| 05/01/25 | ABT | 8-K | Retirement of Abbott Laboratories' Executive Vice President, General Counsel, and Secretary | — | — | — |
| 04/28/25 | ABT | 8-K | Abbott Laboratories Announces Annual Meeting Results | — | — | — |
| 04/16/25 | ABT | 8-K | Abbott Reports First-Quarter 2025 Financial Results with Organic Sales Growth | — | — | — |
| 01/22/25 | ABT | 8-K | Abbott Laboratories Reports Strong Fourth Quarter and Full Year 2024 Financial Results | — | — | — |
| 11/15/24 | ABT | 8-K | Abbott Laboratories Extends Executive Agreements | — | — | — |
| 10/16/24 | ABT | 8-K | Abbott Laboratories Announces Third-Quarter 2024 Results and Raises EPS Guidance | — | — | — |
| 07/18/24 | ABT | 8-K | Abbott Laboratories Reports Q2 2024 Results and Raises Full-Year Guidance | — | — | — |
| 05/01/24 | ABT | 8-K | Robert E. Funck, Jr. to Retire from Abbott Laboratories | — | — | — |
| 04/29/24 | ABT | 8-K | Abbott Laboratories Shareholders Approve Director Elections and Auditor Appointment | — | — | — |
| 04/17/24 | ABT | 8-K | Abbott Reports Q1 2024 Results and Raises Guidance | — | — | — |
| 01/29/24 | ABT | 8-K | Abbott Laboratories Enters New Five-Year Revolving Credit Agreement | — | — | — |
| 01/24/24 | ABT | 8-K | Abbott Laboratories Reports Fourth-Quarter and Full-Year 2023 Financial Results | — | — | — |
ABT filing record
Abbott Laboratories (ABT): 27 8-K filings summarized, the most recent on Aug 20, 2026.
What the 8-K filings said
- Aug 20, 2026 · high impact
On August 20, 2026, Abbott Laboratories announced the settlement of a portion of its litigation involving its specialty formulas for preterm infants. The settlement resolves the Gill case and claims involving approximately 2,000 other individuals for an aggregate amount of approximately $670 million. These agreements…
Abbott Laboratories Settles Portion of Preterm Infant Formula Litigation for $670 Million - Jul 16, 2026 · high impact
Abbott Laboratories announced its second-quarter 2026 results, reporting a 13.0% increase in total sales and a 4.8% increase in comparable sales. The company reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. Abbott raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, up…
Abbott Laboratories Reports Strong Q2 2026 Results and Raises Full-Year EPS Guidance - Apr 27, 2026 · high impact
On April 24, 2026, Abbott Laboratories appointed Kevin Conroy to its Board of Directors and adopted the Abbott Laboratories 2026 Incentive Stock Program, replacing the 2017 Program. The new program allows Abbott to grant various equity-based awards to its directors and employees. Additionally, Abbott's Board amended…
Abbott Laboratories Appoints New Board Member and Adopts New Incentive Stock Program - Apr 17, 2026 · high impact
Abbott Laboratories has announced a proposed settlement in a shareholder derivative lawsuit related to the company's infant formula products. The lawsuit, which has been pending in the United States District Court for the Northern District of Illinois, alleges breaches of fiduciary duty and violations of federal…
Abbott Laboratories Announces Proposed Settlement in Shareholder Derivative Lawsuit - Apr 16, 2026 · medium impact
Abbott Laboratories reported its first-quarter 2026 financial results, showing a 7.8% increase in total sales to $11.164 billion. The company also announced the completion of its acquisition of Exact Sciences, a leader in oncology diagnostics, which is expected to add a new high-growth vertical to Abbott's portfolio.…
Abbott Laboratories Announces First-Quarter 2026 Results and Acquisition of Exact Sciences
SEC filings in the last five years
- 42 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 2 Form 8-K/A